Pdl Biopharma Inc (PDLI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2019 | 03-2019 | 12-2018 | 09-2018 | 06-2018 | |
| Sales | 7,458 | 6,696 | 45,119 | 67,898 | 46,575 |
| Cost of Goods | 4,929 | 3,800 | 11,444 | 11,926 | 14,524 |
| Gross Profit | 2,529 | 2,896 | 33,675 | 55,972 | 32,051 |
| Operating Expenses | 12,715 | 11,915 | 620 | 20,157 | 157,701 |
| Operating Income | -9,257 | -8,219 | 33,499 | 36,741 | -125,126 |
| Interest Expense | 2,984 | 2,955 | 2,895 | 2,866 | 2,811 |
| Other Income | 1,650 | 1,874 | 1,958 | 1,581 | 1,376 |
| Pre-tax Income | -10,591 | -9,300 | 32,562 | 35,456 | -126,561 |
| Income Tax | -2,575 | -848 | 16,283 | 9,900 | -14,265 |
| Net Income Continuous | -8,016 | -8,452 | 16,279 | 25,556 | -112,296 |
| Net Income Discontinuous | 3,502 | 15,069 | N/A | N/A | N/A |
| Minority Interests | -95 | -63 | N/A | N/A | N/A |
| Net Income | $-4,419 | $6,680 | $16,279 | $25,556 | $-112,296 |
| EPS Basic Total Ops | -0.04 | 0.05 | 0.10 | 0.18 | -0.76 |
| EPS Basic Continuous Ops | -0.07 | -0.07 | 0.10 | 0.18 | -0.76 |
| EPS Basic Discontinuous Ops | 0.03 | 0.12 | N/A | N/A | N/A |
| EPS Diluted Total Ops | -0.04 | 0.05 | 0.10 | 0.18 | -0.76 |
| EPS Diluted Continuous Ops | -0.07 | -0.07 | 0.10 | 0.18 | -0.76 |
| EPS Diluted Discontinuous Ops | 0.03 | 0.12 | N/A | N/A | N/A |
| EBITDA(a) | $-6,069 | $-4,998 | $37,575 | $41,185 | $-115,939 |